Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy
EBM, Landmark Research
Clinical Question: As compared to placebo, does the angiotensin-II-receptor agonist (ARB) losartan delay progression to ESRD and improve mortality in patients with type 2 diabetes and nephropathy?